Organization: MSF / Médecins Sans Frontières Access Campaign

This is an archive page containing all the publications filed under Organization: MSF / Médecins Sans Frontières Access Campaign

Want to search through the full database?

Peer-reviewed article from 2016

Scale-Up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges

Grey literature

Untangling the Web of Antiretroviral Price Reductions – 17th Edition, 2014

Grey literature from 2014

Out Of Step: Deadly implementation gaps in the TB response

Grey literature from 2006

Tuberculosis Diagnosis and Drug Sensitivity Testing: An Overview of the Current Diagnostic Pipeline

Grey literature from 2012

The Right Shot: Extending the Reach of Affordable and Adapted Vaccines

Grey literature from 2013

DR-TB Drugs under the microscope: 3rd edition

Grey literature from 2012

DR-TB Drugs under the microscope: 2nd edition

Grey literature from 2014

Vaccinating Children Beyond the ‘Cold Chain’: Extending the heat stability of vaccines

Grey literature from 2013

Untangling the Web of Antiretroviral Price Reductions – 16th Edition, 2013

Grey literature from 2012

Untangling the Web of Antiretroviral Price Reductions – 15th Edition, 2012

Grey literature from 2011

Untangling the Web of Antiretroviral Price Reductions – 14th Edition, 2011

Grey literature from 2014

Striking the right balance: Accessing New Anti-Tuberculosis Drugs in India

Grey literature from 2014

Solutions to improve access to medicines and biomedical innovation through EU trade and R&D policy

Grey literature from 2011

DR-TB Drugs under the microscope: 1st Edition

Peer-reviewed article from 2011

A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries

Grey literature from 2008

Financing Medical Innovation Through Alternative Mechanisms

Grey literature from 2014

Ready, Set, Slow down: New and promising DR-TB drugs are grabbing headlines but not reaching patients: MSF on the policies underpinning the deadly DR-TB treatment gap